Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, is the president of the European Research Initiative on CLL (ERIC), and he spoke to us at the 23rd Congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden, about some of the newest chronic lymphocytic leukemia (CLL) research facilitated by ERIC. These studies include: exploring the benefit of second-line bendamustine and rituximab; and examining the prevalence of BTK and PLCG2 mutations in patients relapsing on ibrutinib. Dr Ghia also discusses the work done by ERIC to demonstrate the importance of incorporating P53 and Ig gene analysis into patient workups to inform treatment plans, and their effort to get the appropriate equipment for such tests in laboratories across the world.
ERIC: current research and initiatives in CLL
